Pregabalin versus crisugabalin for fibromyalgia pain
Official title: Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Crisugabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study
Run by Beijing Tiantan Hospital · NCT07196657 · Data updated 2026-11-12
This trial will test whether pregabalin or the newer drug crisugabalin reduces moderate-to-severe fibromyalgia pain in adults who have not yet used recommended fibromyalgia medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1116 (estimated) |
| Sponsor | Beijing Tiantan Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | September 30, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07196657 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with fibromyalgia per 2016 criteria, moderate-to-severe symptoms (NRS ≥4), refractory to non-pharmacologic therapies, and no prior use of recommended pharmacologic FM treatments, with acceptable liver and kidney function.
✕Probably not a fit
People with prior epilepsy, depression requiring antidepressants, pregnancy or breastfeeding, allergy to the study drugs, severe uncontrolled systemic illness, or eGFR below 30 mL/min/1.73 m² are unlikely to be eligible or to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults meeting the 2016 fibromyalgia diagnostic criteria with baseline pain NRS ≥4 and who are refractory to non‑pharmacological care will be enrolled to receive either pregabalin or crisugabalin per protocol. The study will track changes in pain scores and record adverse events, with routine monitoring of liver enzymes and renal function. Participants must meet laboratory cutoffs (AST/ALT <2×ULN, eGFR ≥30 mL/min/1.73 m²) and will be followed at participating hospital sites in Beijing. The goal is to compare pain relief and tolerability between the established drug pregabalin and the newer selective α2δ ligand crisugabalin.
Why it matters
Potential benefit: If crisugabalin is safer or more effective than pregabalin, patients could gain a better-tolerated option that provides greater pain relief for fibromyalgia.
How similar studies have gone: Pregabalin is an established but only partially effective treatment (about 25–40% pain relief rate), while crisugabalin has shown promise in animal studies and early clinical work but lacks robust evidence in fibromyalgia.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with FM according to the 2016 Revisions to the 2010/2011 FM diagnostic criteria; * Aged over 18 years old; * Suffering from moderate to severe FM, refractory to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM; * Baseline numeric rating scale (NRS) score of 4 or higher; * Aspartate aminotransferase and alanine aminotransferase levels below twice the upper limit of normal range; * Estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m²; * Willingness to provide informed consent and adequate cognitive and language capabilities to meet all study requirements; Exclusion Criteria: * Previous allergic reactions to pregabalin, crisugabalin, or any of their excipients; * Prior diagnosis of epilepsy or depression requiring antidepressant therapy; * Women who are pregnant or breastfeeding; * Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment; * Suffering from acute or chronic pain disorders other than FM.
Where it's running
-
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China Recruiting
Study contacts
- Study coordinator: Fang Luo, M.D.
- Email: 13611326978@163.com
- Phone: +86 13611326978
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregabalin plus dexmedetomidine for reducing pain and improving sleep in fibromyalgia
This trial will try combining pregabalin with dexmedetomidine to reduce pain and improve sleep in adults with moderate-to-severe fibromyalgia.
-
Pregabalin combined with toludesvenlafaxine for fibromyalgia pain
This trial will see if adding toludesvenlafaxine to pregabalin improves pain relief without causing more side effects for adults with moderate to severe fibromyalgia.
-
Pregabalin plus venlafaxine for fibromyalgia pain
This trial tests whether adding venlafaxine to pregabalin gives better pain relief for adults with moderate-to-severe fibromyalgia than pregabalin alone.
-
Pregabalin plus desvenlafaxine for fibromyalgia pain
This test will try whether adding desvenlafaxine to pregabalin gives better pain relief for adults with moderate to severe fibromyalgia.
-
Comparing pregabalin and mirogabalin for fibromyalgia pain
This trial will test whether mirogabalin or pregabalin better reduces pain and causes fewer side effects in adults with moderate-to-severe fibromyalgia.
-
Respiratory Function in Fibromyalgia: A Look at Breath and Muscle Health in Women
This study compares respiratory function, muscle strength, and quality of life between women with fibromyalgia and healthy women to see if fibromyalgia affects breathing and muscle performance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.